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Abstract
BACKGROUND: Today, coronavirus disease (COVID)-19 has become a worldwide pandemic. People living with 
HIV are one of the special populations who are susceptible to COVID-19 infection and suspected of having a poor 
prognosis.
CASE REPORT: We reported two serial cases of COVID-19 with HIV coinfection. First case was a COVID-19 patient 
coinfected with HIV who had received anti-retroviral therapy (ARV) and had an absolute CD4 cell count of 781 cells/
uL. Patient was found with mild symptoms of COVID-19 and had normal laboratory results and chest X-ray. Patient 
was declared cured after 26 days of treatment in isolation room with complete clinical improvement since day 5 
of isolation. Second case was a COVID-19 with HIV coinfection that had not yet received ARV therapy and had 
absolute CD4 cell count of 155 Cell/uL. Patient came with moderate clinical symptom of COVID-19 and experienced 
secondary bacterial and tuberculosis infection. Patient was declared cured of COVID-19 on the 8th day of treatment 
with clinical improvement but still needed further treatment in a non-isolation room.
CONCLUSION: Clinical characteristics of COVID-19 in HIV and non-HIV patients are the same. A history of ARV 
therapy and CD4 count did not affect the length of isolation until a negative result on two reverse-transcription-
polymerase chain reactions, but could affect prognosis and clinical severity due to the high risk of secondary infection 
in HIV-positive patients without ARV or HIV/AIDS who had a CD4 count ≤200 cell/uL.
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Introduction
Coronavirus (CoV) disease (COVID)-
19 infections that are caused by the severe acute 
respiratory syndrome (SARS)-COV-2 virus today 
become a worldwide pandemic [1]. Patients who had 
underlying diseases such as diabetes mellitus (DM), 
chronic kidney disease, hypertension, heart disease, 
and chronic lung disease based on epidemiological data 
more susceptible to get COVID-19 infection with more 
severe prognosis than the general population due to 
chronic systemic immunodeficiency and inflammatory 
conditions in patients [2]. Other immunodeficiency 
conditions such as people living with HIV/AIDS (PLWHA) 
are also thought to have a higher risk of becoming 
infected with COVID-19 with a worse prognosis.
Epidemiological facts regarding this matter are 
still inconclusive [3]. Articles about COVID-19 infection 
in HIV/AIDS patients still provide various results in 
terms of susceptibility to COVID-19 infection, clinical 
characteristics, symptom severity, and prognosis. In the 
COVID-19 with HIV coinfection case series written by 
Cooper et al. in 2020 said that viral load and CD4 count 
were factors that influenced the severity of symptoms, but 
not the individual’s susceptibility to COVID-19 infection. 
There was also another hypothesis which states that HIV 
is a protective factor for organ damage due to cytokine 
storms in COVID-19 patients with HIV/AIDS [4]. Research 
by Karmen-Tuohy et al. in 2020 with a number of subjects 
dominated by COVID-19 patients with controlled HIV 
infection showed no significant difference in mortality 
rates in HIV patients compared to controls (population 
without HIV) [5]. Another study article by Harter et al. in 
2020 found significantly higher mortality, hospitalization, 
and critical infection rates in patients with COVID-19 
coinfected with HIV than in the general population [6].
We reported two serial cases of COVID-19 with 
HIV coinfection. First case was a COVID-19 patient with 
HIV who was already undergoing anti-retroviral therapy 
(ARV) therapy and the second case was a COVID-19 
patient with HIV who had not received ARV treatment.
Case
First case was a 67-year-old woman who 
came to the COVID-19 polyclinic with chief complaints 
sore throat and cough without sputum for last 3 days. 
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Patient said that she had a history of close contact with 
a confirmed case of COVID-19. She is a PLWHA who 
regularly takes ARVs, rilpivirine 25 mg every 24 h, and 
tenofovir/emtricitabine 300 mg/200 mg every 24 h and 
has hypertension as other comorbidity and has been 
controlled with Amlodipine 10 mg every day. Physical 
examination was in normal limits. Twice reverse-
transcription-polymerase chain reaction (RT-PCR) 
nasopharyngeal swab diagnostic were performed 
and both tests were positive. Patient was hospitalized 
after being confirmed positive for COVID-19 through 
a nasopharyngeal RT-PCR swab examination. Both 
nasopharyngeal swab RT-PCR examined by kit that used 
Nucleocapsid 1, Nucleocapsid 2, and RNA-dependent 
RNA polymerase (RdRp) viral component as protein 
target. First RT-PCR swab obtained Cycle Treshold (CT) 
value for each target gene ware, respectively, 20.19; 
20.84; and 27.82. Second RT-PCR swab obtained CT 
values for each target gene were, respectively, 18.55; 
20.30; and 27.12. Complete blood count performed on 
the 1st day of hospitalization was within normal limits, 
there was an increase in the Ferritin value of 480.30 and 
C-Reactive Protein of 5.87. Liver function tests showed 
a slight increase in aspartate aminotransferase (AST), 
which was 41.4, while the alanine aminotransferase 
(ALT) value was within normal limits. Renal function tests 
were also found within normal limits. Patient’s absolute 
CD4 count was 781 cells/uL. Patient also performed a 
chest X-ray at the time of admission to the hospital, with 
the result was no lung abnormality (Figure 1a).
During hospitalization, ARV therapy was 
continued. Patients received hydroxychloroquin at a 
dose of 400 mg every 12 h orally on the 1st day and 
continued with 200 mg every 12 h until the 10th day. 
Patients continue consume Amlodipine 10 mg every 24 
h regularly and other symptomatic therapy. Evaluation 
of the RT-PCR swab examination was carried out every 
5–7 days. The evaluation of the X-ray examination 
was carried out on the 16th day of hospitalization with 
an normal lung configuration result (Figure 1b). The 
patient gets full recovery in the 5th day of hospitalization 
and was declared cured after 26 days of treatment.
Second case was a woman, 43 years old, who 
came to the Emergency Unit with an acute complaint of 
fever since 6 days, cough with phlegm, and chest hard 
to breath since 1 day before admission accompanied 
by decreased appetite. Chronic symptom in the form 
of weight loss of 10 kg within 1 month was also found. 
Patient was currently undergoing intensive phase of anti-
tuberculosis treatment for lymphadenitis tuberculosis 
and had been diagnosed with HIV, but has not received 
ARV treatment. The history of contact with a confirmed 
COVID-19 person was unknown, but the patient lives 
in a local transmission area of COVID-19. On physical 
examination, there was an increase in body temperature 
(38.6°C), increase in the respiratory rate of 22 times/min, 
SpO2 93% room air, and raunchy on lung auscultation 
in basal of the right lung. Laboratory examination 
was found normal leukocyte value with an increase in 
neutrophils percentage (81%), lymphopenia (0.42 103/
µL), moderate anemia (7.58 g/dl), and thrombocytopenia 
(92.95 103/µL). There was also an increase in the AST 
and ALT values, respectively, 386.8 and 52.60. Patient’s 
absolute CD4 count at admission was 155 cells / uL. 
A chest X-ray on the 1st day of hospitalization showed 
a reticular pattern in both lung fields (Figure 2a). 
Patient was diagnosed with a suspected COVID-19 
accompanied by community pneumonia and was treated 
in an isolation room. Furthermore, a diagnostic RT-PCR 
nasopharyngeal swab examination was carried out. 
First RT-PCR was positive for COVID-19 and second 
RT-PCR was found negative for COVID-19. RT-PCR 
examination used kit with the non-sturctural protein 1 
(NSP-1) gene as a positive control. First RT-PCR swab 
obtained CT values for positive control and internal 
control were 37.98 and 33.56, respectively. The patient 
was diagnosed with confirmed COVID-19 and treatment 
was continued in an isolation room. RT-PCR swab 
evaluations were carried out every 5–7 days and chest 
X-ray evaluations were carried out when the patient was 
declared cured of COVID-19.
During hospitalization, patients received 
empiric antibiotic therapy in the form of Cefoperason-
sulbactam 1 g every 12 h intravenously and Levofloxacin 
750 mg every 24 h intravenously for 7 days, symptomatic 
therapy, and continued anti-tuberculosis treatment. 
Patient did not receive antiviral treatment. Patient was 
declared cured of COVID-19 on the 8th day of treatment 
after two negative RT-PCR results. Patient left the 
isolation room with partial clinical improvement and 
further treatment was carried out in the non-isolation 
Figure 1: Chest X-ray of  the  first  patient,  (a)  1st day of admission; 
(b) 6th day after hospitalization
a b
Figure 2: Chest X-ray of second patient, (a) 1st day of admission; 
(b) the last day of hospitalization
a b
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room. The evaluation of the chest X-ray when the 
patient was declared cured showed a reduction of lung 
infiltrate (Figure 2b).
Discussion
Today, there have been various articles that 
discuss about characteristics of COVID-19 infection in 
HIV patients [4]. Immunodeficiency in HIV is thought 
to be a factor that increases the risk of COVID-19 
infection. CD4 count and viral load are also thought to 
be factors that influence the poor prognosis in patients, 
but several articles have shown various results [7]. 
In this article, two case series of COVID-19 with HIV 
coinfection were reported comparing HIV cases with 
ARVs and HIV without ARVs.
In a study conducted by Huang et al. in 
2019 regarding the clinical characteristics of COVID-
19 patients in Wuhan, the median age of COVID-19 
patients was found to be 49 years. That study used 41 
subjects with 32% of them having underlying diseases 
such as DM, hypertension, and cardiovascular disease, 
but none of the subjects had HIV infection. It was 
found median time of hospital stay was 7 days after 
symptom onset and experienced dyspnea 8 days after 
symptom onset. It also mentioned some of the major 
symptoms experienced by the patients, including fever 
(98% subjects), cough (76% subjects), and myalgia or 
fatigue in 44% of subjects [2]. Another study conducted 
by Harter et al. in 2020 regarding the characteristics of 
COVID-19 cases with HIV coinfection obtained similar 
median age with the previous studies; it was 48 years 
with range of 26–82 years. In our study, all subjects 
had received ARV therapy and had a median CD4+ 
count 670/mm3. It also mentioned some of the major 
symptoms experienced by the patient; they were cough 
(78%), fever (69%), atralgia or myalgia (22%), and sore 
throat (22%) [6]. A case report by Patel et al. in 2020 
regarding a COVID-19 patient with HIV coinfection aged 
37 years who had an absolute CD4 cell count 34 cells/uL 
had experiencing symptoms such as fever, dry cough, 
and chest pain since 1 month before being admitted 
to the hospital. Physical examination found that high 
body temperature of 38.8°C, oxygen saturation (SpO2) 
of 85–90% on ambient air, with high respiratory rate (40 
beats/min), and pulse rate were 119 beats/min [8].
Demographic and clinical characteristics of 
two patients in this case report were similar to those of 
the patients in other case reports. COVID-19 patients 
with HIV and without HIV have similar demographic 
and clinical characteristics. Patients who have received 
ARV and have CD4 + count ≥200 cells /uL showed mild 
COVID-19 clinical symptom with cough without phlegm 
and sore throat. Patients who have not received ARVs 
with CD4 + counts <200/uL showed moderate clinical 
symptom of COVID-19 with cough, fever, accompanied 
by hard to breath sensation and increase in respiratory 
rate. Based on the case report by Patel et al. in 2020, 
clinical severity of the second patient could be affected 
by the possibility of secondary infection. Viremia was 
also cannot rule out as a caused of more severe clinical 
symptom in the second patient [8].
First patient had normal laboratory results and 
chest X-rays. Second patient’s laboratory examination 
showed an increase in neutrophils percentage, 
lymphopenia, and thrombocytopenia accompanied by a 
reticular pattern on chest X-rays. Second patient also had 
chronic symptoms such as weight loss associated with 
lymphadenitis tuberculosis beside signs of acute infection 
caused by bacteria or other opportunistic infections.
In a study conducted by Huang et al. in 2019 
on the COVID-19 population without coinfection, only 
four patients (10%) had secondary infections and 
required intensive care. Laboratory results showed 
normal leukocyte values (in 45% of patients), with 
an average absolute neutrophil count was 5 × 103/L, 
leukopenia occurred in 63% of patients, normal platelet 
values were found in 95% of patients, and dominantly 
liver and kidney function were found. Within normal 
limits with a mean procalcitonin value was 0.1. A case 
series in Barcelona, Spain regarding COVID-19 with 
HIV coinfection by Blanco et al. in 2020 comparing four 
patients who were taking ARVs routinely and had an 
absolute CD4 + count> 200/uL and one patient who 
had not taken ARVs and had a CD4 + count <200/uL. 
Two patients who had received ARV therapy had mild 
clinical symptom without laboratory and chest X-ray 
abnormalities, two patients who received ARV had 
moderate symptoms, and one patient who had no ARV 
and had a CD4+ 13 Cell/uL count had severe COVID-
19 symptoms with secondary bacterial infection signs 
such as increase in leukocyte to 14,670 cells per 103/L. 
Lymphopenia occurred in two cases with ARV and one 
case without ARV with the lowest lymphocyte count value 
were 900 cells per 103/L [9]. Case reports by Wang et al. 
in 2020 have different characteristics. They reported 
COVID-19 patients with HIV coinfection and a CD4+ 34 
Cell/uL count had a severe clinical presentation but no 
leukocytosis or signs of secondary infection, especially 
bacterial infection [10]. Other secondary infections 
that can occur in HIV patients are Pneumocystis 
carinii (Pneumocystis pneumonia [PCP]), tuberculosis, 
Hepatitis B, Hepatitis C, Cryptococcal Meningitis, and 
Toxoplasmosis [11]. It can be considered to conduct a 
clinical evaluation of the infection if you get a COVID-19 
patient with HIV coinfection to improve the prognostic 
outcome of the patient, especially HIV/AIDS patients 
who have a CD4 + count <200 Cells/uL.
In this case report, first case had normal 
laboratory and chest X-ray result, while second case 
showed normal leukocyte values accompanied by 
increased in neutrophil, lymphopenia, moderate anemia, 
and thrombocytopenia. A normal leukocyte value in HIV 
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patients does not absolutely rule out the possibility of 
secondary infection, especially bacterial infection. 
Based on a study conducted by Huson et al. in 2016 in 
patients with bacteremia, it was found that increasing of 
leukocyte average in HIV patients was lower than non-
HIV patients. That study was conducted on patients with 
a mean CD4+ count 150 cells/uL [12]. In case series 
reported by Blanco et al. in 2020, HIV patients who had a 
CD4 + count >200 cell/uL and were already taking ARVs 
routinely showed a higher increase in leukocytes than 
HIV patients with CD4+ counts <200 cells/uL and had not 
received ARVs [9]. Lymphopenia and thrombocytopenia 
were accompanied by a reticular pattern in chest X-ray 
consistent with viral infection sign. Mild anemia can be 
caused by chronic inflammation due to tuberculosis 
and HIV. Nutritional intake from food can also affect 
the occurrence of anemia in patients. Various articles 
have reported no significant association between HIV 
conditions and the risk of SARS-COV-2 infection; 
however, severe lymphopenia in HIV/AIDS patients with 
COVID-19 can affect the severity of symptoms. Based 
on research conducted by Qin et al., it was found that 
the number of B cells, T cells, and NK cells significantly 
decreased in COVID-19 patients. If coupled with HIV/
AIDS can cause severe lymphopenia, thereby increasing 
the risk of severe pneumonia and secondary infection in 
HIV patients which affect the severity of symptoms and 
poor prognosis [13].
The SARS-COV2 viral nucleic acid RT-PCR 
test from nasopharyngeal swab is currently the 
standard method to diagnosed COVID-19 [14]. First 
patient had twice positive diagnostic swab PCR results, 
while the second patient had only one positive PCR 
diagnosis. SARS-COV-2 RT-PCR examination result 
can be influenced by various factors, such as the type of 
specimen, specimen collection time, number of viruses, 
and examination tool or kit [15].
Specimen type can determine the rate of 
positivity for RT-PCR examinations in COVID-19. There 
are several types of specimens that can be used; they 
are Bronchoalveolar lavage (BAL), Fibro bronchocope 
biopsy, sputum, nasopharyngeal swab, oropharyngeal 
swab, feces, and urine. Nasopharyngeal swab and 
oropharyngeal swab are two types of specimens 
that are commonly used as samples for COVID-19 
testing in the world, especially in Indonesia. This is 
due to easy sampling process with a high positive 
rate [15]. Based on the article written by Wang et al. 
in 2020, the nasopharyngeal and oropharyngeal swab 
positivity rates were 63% and 32%, respectively, where 
nasopharyngeal swab was superior to oropharyngeal. 
Specimens derived from BAL and sputum are two types 
of specimens that have the highest rate of positivity 
compared to other specimen types with the percentage 
of positivity, respectively, 93% and 72% [15]. 
Systematic review article with meta-analysis method 
also shows the same thing, specimens derived from 
nasopharyngeal swabs have a lower sensitivity than 
sputum, where sputum has a sensitivity of 97.2% with 
a 95% confidence interval of 90.3–99.7% [16]. In this 
case, a negative result on one of the diagnostic swab 
examinations of the second patient could be due to the 
rate of positivity of the specimen used.
Specimen collection time and number of 
viruses can also affect the SARS-COV-2 RT-PCR 
results. Timing of specimen collection is related to the 
presence of the SARS-COV2 virus in the examination 
specimen [16]. Research conducted by Wang et al. in 
2020 regarding differences in shedding duration for 
sputum and nasopharyngeal swabs specimens found 
a correlation between viral shedding time and the 
positivity of each specimen. In this study, it was found 
that median duration of viral shedding from sputum was 
34 days, while viral shedding from nasopharyngeal swab 
specimens was 19 days. Nine patients found positive 
sputum specimens after negative nasopharyngeal 
swab examination. Chronic lung disease and systemic 
steroid use was also found to be associated with viral 
detection in sputum specimens; however, HIV/AIDS 
was not mentioned as a factor affecting the location 
of viral shedding [17]. Specimen collection time is also 
related to the amount of virus in the nasopharyngeal 
specimen. In a study by Lirong et al. in 2020, the 
highest number of viruses in nasopharyngeal swab 
specimens was found on days 3–6 after the onset of 
symptoms and began to decline on the 7th day after 
symptoms [18]. The incubation period must also be 
taken into account as a factor for bias in the results of 
nasopharyngeal swabs [19]. Hence, a negative result 
on nasopharyngeal RT-PCR swab can also be caused 
by the location of the viral shedding which is not suitable 
for the specimen and the time of specimen collection.
There are various kits that are used in Indonesia 
with different gene targets or primers [20]. Two patients 
on the diagnostic swab used a different kit, where first 
patient used a kit that detected N1, N2, and RdRp as 
gene target while the second patient used a kit targeting 
the NSP-1 gene as gene target. Target gene largely 
determines the sensitivity and specificity of an assay. 
Multitarget RT-PCR can improve the accuracy of the 
RT-PCR results, because negative results can be found 
in one of the target genes if there is a mutation in that 
section [21]. Second patient had one negative RT-PCR 
diagnostic nasopharyngeal swab. This can be affected 
by the RT-PCR kit used. Based on research conducted 
by Chan et al. in 2020 regarding the detection accuracy 
of the NSP-1 gene for COVID-19 diagnostics in 101 
clinical specimens, the test sensitivity and specificity 
were 93.1% (95% confidence interval 86.2–97.2%) and 
100% (95% confidence interval 92.9–100%), so there 
is still a possibility of false negatives in approximately 
6.9% of the specimens [22]. The CT value of the second 
patient was higher than first patient, but could not be 
compared because of differences in target genes in 
the two RT-PCRs kit. These results can be used to 
illustrate the relationship between baseline CT values 
and the length of time to achieve negative RT-PCR 
nasopharyngeal swab evaluation results.
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Recommendation therapy for COVID-19 
patients with HIV coinfection is similar to COVID-19 
without HIV coinfection [14]. The high risk of secondary 
infection in HIV/AIDS patient’s makes the optimization 
of secondary infection therapy was very important [4]. 
Giving systemic steroids to COVID-19 patients with 
HIV coinfection are still recommended, especially 
in patients with severe clinical COVID-19 or with 
secondary infection in the form of severe PCP, although 
systemic steroid administration in a study conducted 
by Huang et al. in 2020 and Wang et al. in 2020 said 
could be slowering viral clearance and prolong viral 
shedding period [2], [17]. The recommendations issued 
by British and American health institutions for people 
with HIV during the pandemic are to ensure that they 
have a supply of ARVs and that they are vaccinated 
against Influenza and Pneumococci regularly. Until 
now, there have been no specific reports regarding the 
relationship between the types of ARVs used and the 
severity of COVID-19 symptoms in patients with HIV, 
but there is a case series that show clinical differences 
in patients with different history of ARVs [9]. A case 
series report by Blanco et al. in 2020 showed two 
patients taking the combination of the ARVs tenofovir 
alafenamide, emtricitabine, and darunavir-boosted 
Cobicistat had mild symptoms of COVID-19 and two 
patients taking the combination of the ARV abacavir, 
lamivudine, and dolutegravir had a moderate to severe 
COVID-19 presentation and require intensive care [9]. 
Combination of Lopinavir and Ritonavir in in vitro studies 
can shorten viral shedding period, but its effectiveness 
in clinical studies of COVID-19 has not been shown to 
significantly increase patient outcomes compared to 
standard therapy [23].
The outcome of COVID-19 patients can 
be assessed based on the length of time to achieve 
negative result in nasopharyngeal RT-PCR swab 
and morbidity and mortality risk. First patient had a 
negative RT-PCR nasopharyngeal swab on the 26th 
day of treatment and the second patient had a negative 
result on the 8th day of treatment. A case report by 
Wang et al. in 2020 regarding a COVID-19 patient with 
HIV coinfection who had a CD4 + count <200 Cells/
uL reported something similar to the second case, it 
was only getting positive results on the first RT-PCR 
and negative on 3 RT-PCR nasopharyngeal swab 
evaluation. It is due to the baseline value of each CT, but 
cannot be compared because of using a kit with different 
target genes. Another possibility is second patient’s 
viral shedding on the day of evaluation was found in the 
sputum, so it was not detected in the nasopharyngeal 
swab specimen. Two cases reported by Menghua et al. 
in 2020 showed long cases of COVID 19 and it took 
28 days to get a negative RT-PCR swab, but, in this 
case, RT-PCR was carried out on a sputum specimen. 
This can be due to prolonged viral shedding in patients 
associated with damage to cellular function of CD4 + 
cells even though the CD4 + cell count is within normal 
limits [24]. The outcome of mortality risk in several 
articles is still inconclusive. Systematic review article on 
COVID-19 in HIV patients by Cooper et al. 2020 said 
that patients with HIV with an undetectable viral load 
and an adequate CD4 cell count had no worse outcome 
than the general population. Uncontrolled HIV infection 
and AIDS are one of the factors in the poor prognosis 
of patients with COVID-19. This is associated with the 
occurrence of bacterial superinfection in patients [4]. 
Another study by Karmen-Tuohy et al. in 2020 with the 
number of subjects dominated by COVID-19 patients 
with controlled HIV showed no significant difference 
in mortality rates between HIV patients and control 
(population without HIV) [5]. Another study article by 
Harter et al. in 2020 found significant higher mortality, 
hospitalization, and critical infection rates in patients 
with COVID-19 with HIV than general population. In 
those studies, mortality rate in COVID-19 patients with 
HIV was 9% [6].
Conclusion
The clinical and demographic characteristics of 
COVID-19 in HIV and non-HIV patients are the same. A 
history of antiretroviral therapy and CD4 count did not 
affect the outcome of the length of care until a negative 
result on two RT-PCRs, but could affect prognosis 
and clinical severity due to the high risk of secondary 
infection in HIV-free or HIV/AIDS patients who had a 
CD4 count ≤200 Cell/uL.
Future Research
Further research is needed regarding: (1) The 
accuracy of RT-PCR swab examinations in various 
specimens, especially in HIV/AIDS patients who 
have a CD4 + count <200/uL; (2) the effect of various 
combination ARV therapy in COVID-19 patients with 
HIV coinfection on the severity of clinical symptoms and 
the prognosis of COVID-19 patients; (3) antiviral and 
supportive therapy options in COVID-19 patients with 
HIV coinfection; (4) patient prognosis COVID-19 with 
HIV coinfection and factors affecting the prognosis.
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